Altamira Therapeutics (CYTO) H1 2025 earnings summary

Executive summary

• Strategic shift to focus on RNA delivery business, with a planned partial spin-off of the Swiss subsidiary ATAG to attract private equity investment and transform the parent into a holding company.

• Expanded RNA delivery client base and advanced the xPhore platform, including new Cyclophore technology for circular RNA applications.

• Legacy assets, including Bentrio nasal spray and AM-125/AM-111, are being monetized or transitioned, with progress in manufacturing and regulatory approvals.

• Continued cost structure adjustments and furthered development of legacy assets, including Bentrio and AM-125.

Financial highlights

• Operating loss for H1 2025 was $2.6 million, down 32.9% year-over-year, driven by lower G&A and R&D expenses.

• Net loss decreased 64.6% to $1.5 million, aided by $1.7 million in finance income from currency appreciation.

• Cash used in operations dropped 56.8% to $1.4 million; cash and equivalents at June 30, 2025, were $4,000.

• Shareholders’ equity was $4.1 million at mid-2025, down from $6.6 million at year-end 2024.

• Basic and diluted loss per share for H1 2025 was $(0.31), compared to $(2.11) in H1 2024.

Outlook and guidance

• Anticipates significant reduction in operating expenses post-spin-off of ATAG.

• Funding expected from cash, sale of ATAG shares, legacy asset monetization, and service provision.

• Financial guidance will be updated as material developments occur, especially regarding the spin-off.